Cadenza Bio

Executive Summary

Cadenza Bio is a preclinical-stage biotechnology company pioneering novel oral small-molecule agonists of Estrogen Receptor β (ERβ) to treat demyelinating and inflammatory diseases. Founded in 2020 and based in San Diego, the company aims to halt disease progression and promote repair in conditions such as multiple sclerosis (MS) and endometriosis, moving beyond symptom management. ERβ represents a promising but underexplored target with potential neuroprotective and anti-inflammatory effects. Cadenza's approach leverages the receptor's role in remyelination and immune modulation, offering a differentiated mechanism versus current therapies. While still preclinical, the company's focus on oral administration and disease modification positions it for significant impact if successful. However, given the early stage and lack of disclosed funding or partnership, the risk remains high, warranting a moderate conviction score.

Upcoming Catalysts (preview)

• Q2 2026Presentation of preclinical proof-of-concept data in MS and endometriosis models60% success
• Q4 2026IND-enabling studies initiation or completion40% success
• H1 2027Series A financing or strategic partnership announcement50% success